ArdorComm Media Group

Monday, July 7, 2025 1:52 AM

JN.1

India Sees Uptick in COVID-19 Cases: Active Infections Near 4,000, Deaths Reported Across Key States

Ardorcomm news

India is witnessing a steady rise in COVID-19 infections, with active cases reaching 3,961 as of Monday, June 2—a jump of 566 cases from the previous day, according to data from the Ministry of Health and Family Welfare (MoHFW). The recent surge is driven primarily by states like Kerala, Maharashtra, and Delhi, which are reporting the highest case numbers. Since the start of the year, the country has registered 32 COVID-related deaths, including four in the last 24 hours. One fatality each was reported from Delhi, Kerala, Maharashtra, and Tamil Nadu. The deceased include a 22-year-old woman from Delhi with a history of post-tuberculosis complications and a 44-year-old man from Maharashtra suffering from acute respiratory distress and aortic valve problems. While Kerala confirmed another death, specific details are awaited. Delhi Records Steepest Daily Spike; Tamil Nadu, Karnataka Also Report Fatalities Delhi saw the most significant daily rise in active infections among major states, adding 47 new cases and logging one death. Tamil Nadu, with 189 active cases, reported the passing of a 25-year-old man with underlying bronchial asthma and acute kidney complications. Karnataka, currently reporting 253 active cases, recorded a fresh fatality, while Uttar Pradesh reported two deaths and has 157 active cases. In total, 16 states and Union Territories have recorded COVID-related deaths in 2025. However, the majority of cases remain mild, with limited hospital admissions. Kerala Leads in Caseload; Maharashtra, West Bengal Also on High Alert Kerala continues to report the highest number of active COVID-19 cases at 1,435, rising from 1,336 the previous day. Maharashtra follows with 506 active cases, and Delhi with 483. West Bengal has also seen a surge, reporting 331 active infections. Other notable figures include: Gujarat: 338 Karnataka: 253 Tamil Nadu: 189 Uttar Pradesh: 157 Rajasthan: 69 States like Madhya Pradesh (23), Haryana (28), and Odisha (12) have recorded smaller increases. In the last 24 hours, 203 patients have recovered, pushing the total number of recoveries and migrations this year to 2,188. Authorities Urge Caution, Not Panic Health experts and officials maintain that the situation is under control, emphasizing that most new cases are mild and manageable at home. Dr. Rajiv Behl, Director General of the Indian Council of Medical Research (ICMR), reassured the public that while increased vigilance is necessary, there’s no immediate cause for alarm. The rise in cases coincides with the detection of new Omicron sub-variants—LF.7, XFG, JN.1, and NB.1.8.1—identified in genome sequencing studies from western and southern India. These have been classified by the World Health Organization as “Variants Under Monitoring,” indicating they don’t currently pose a significant global threat. Preparedness Measures in Place as Precaution In response, state health departments—particularly in Delhi, Maharashtra, and Kerala—are ramping up hospital readiness and reviewing medical supply logistics. Citizens, especially vulnerable groups such as the elderly and those with pre-existing health issues, are being encouraged to wear masks in crowded or poorly ventilated settings. Experts stress that while the virus is spreading faster due to more contagious but less severe sub-variants, preventive strategies such as timely testing, vaccination, and community awareness remain key to containing its impact. Though the overall caseload is still far lower than during peak waves, the recent tenfold increase over two weeks underscores the need for continued monitoring, public cooperation, and proactive measures to avoid another significant outbreak. Source: Economic Times Photo Credit: iStock   

India Sees Uptick in COVID-19 Cases: Active Infections Near 4,000, Deaths Reported Across Key States Read More »

New COVID-19 Subvariants NB.1.8.1 and LF.7 Detected in India: INSACOG Report

India has recorded the presence of two newly emerging COVID-19 subvariants—NB.1.8.1 and LF.7—according to recent data released by the Indian SARS-CoV-2 Genomics Consortium (INSACOG). While these variants are currently categorized as Variants Under Monitoring by the World Health Organization (WHO), they have been linked to the recent surge in COVID-19 cases across China and parts of Asia. As per the INSACOG data, a single case of NB.1.8.1 was identified in Tamil Nadu in April, while four cases of LF.7 were reported from Gujarat in May 2025. Despite these new detections, the dominant strain circulating in India remains JN.1, accounting for approximately 53% of the tested samples. It is followed by BA.2 (26%) and other Omicron-related variants (20%). Preliminary assessments by WHO suggest that NB.1.8.1 poses a low global public health risk, but the subvariant carries spike protein mutations—A435S, V445H, and T478I—that may enhance both transmissibility and the ability to evade immune responses. As of May 19, India reported 257 active COVID-19 cases. A high-level review meeting was recently convened, chaired by the Director General of Health Services, with participation from the ICMR, National Centre for Disease Control, and other leading health agencies to monitor the evolving situation. Meanwhile, certain states have shown localized spikes. Delhi reported 23 new cases, Andhra Pradesh had four, Telangana confirmed one, and Bengaluru recorded a positive case in a nine-month-old infant, reflecting a steady rise over the last 20 days. Kerala, in particular, reported 273 cases in May alone. Source: PTI

New COVID-19 Subvariants NB.1.8.1 and LF.7 Detected in India: INSACOG Report Read More »

Scientists Concerned About New COVID Variant ‘JN.1’ with Increased Infectiousness and Potential Vaccine Immunity Evasion

Scientists are expressing concern about the latest COVID-19 variant, named ‘JN.1’, as it appears to be more infectious and potentially capable of evading vaccine immunity. This variant was first identified in Luxembourg on August 25, 2023, and has since been detected in several countries, including England, Iceland, France, and the United States. What particularly worries scientists is the significant number of genetic differences in JN.1 compared to other prominent COVID strains like XBB.1.5 and HV.1. XBB.1.5 is the primary target of the latest vaccine boosters in the United States, and most new variants are descendants of this strain, indicating that existing vaccines are effective against them. HV.1, while somewhat different from XBB.1.5, shares similarities with its parent strain. However, JN.1 stands out due to its substantial divergence. In comparison to XBB.1.5, HV.1 has ten additional unique mutations, but JN.1 boasts a striking 41 additional unique mutations. A significant portion of these mutations is found in the spike protein of the virus, which is associated with increased infectivity and potential immune evasion. This raise concerns that current vaccines may not be as effective against this variant. Dr. Thomas Russo, the chief of infectious diseases at the University of Buffalo in New York, stated that JN.1’s spike protein mutation makes it particularly adept at evading the immune response, which could lead to a higher risk of infections. Moreover, there is some evidence suggesting that JN.1’s parent variant, BA.2.86, may be more transmissible than earlier versions of the virus. This high degree of variability in the spike protein, which was first observed in the alpha and beta versions of SARS-CoV-2 in 2021, is a noteworthy aspect of JN.1’s genetic makeup. While these developments raise concerns, the U.S. Centers for Disease Control and Prevention (CDC) have indicated that initial data suggests updated COVID vaccines should still provide protection against JN.1. They also stated that treatments and testing measures are expected to remain effective against this variant, based on an analysis from the federal government’s SARS-CoV-2 Interagency Group.

Scientists Concerned About New COVID Variant ‘JN.1’ with Increased Infectiousness and Potential Vaccine Immunity Evasion Read More »